MY MEDICAL SUITCASE RADIOTHERAPY
The development of treatment and diagnostic techniques allows for better assessment of cancers.
Typically, a distinction was made between localised and metastatic cancers.
Among metastatic cancers, there are currently cancers with few distant metastases (typically less than 5). They are known as what is called oligometastatic.
Currently, it is demonstrated by phase II trials that local treatment of metastases by stereotactic radiotherapy prolongs the response to treatment and improves patient survival.
Stereotactic radiotherapy is the primary treatment in this situation because it allows the delivery of so-called “ablative” doses in a few sessions, and its toxicity is very limited.
It is currently suspected that radiotherapy and immunotherapy have a joint effect on the immune system.